DongKoo Bio & Pharma Balance Sheet Health
Financial Health criteria checks 4/6
DongKoo Bio & Pharma has a total shareholder equity of ₩110.4B and total debt of ₩41.9B, which brings its debt-to-equity ratio to 38%. Its total assets and total liabilities are ₩191.1B and ₩80.7B respectively. DongKoo Bio & Pharma's EBIT is ₩14.6B making its interest coverage ratio 10.1. It has cash and short-term investments of ₩22.9B.
Key information
38.0%
Debt to equity ratio
₩41.95b
Debt
Interest coverage ratio | 10.1x |
Cash | ₩22.90b |
Equity | ₩110.44b |
Total liabilities | ₩80.66b |
Total assets | ₩191.10b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A006620's short term assets (₩88.4B) exceed its short term liabilities (₩73.3B).
Long Term Liabilities: A006620's short term assets (₩88.4B) exceed its long term liabilities (₩7.3B).
Debt to Equity History and Analysis
Debt Level: A006620's net debt to equity ratio (17.2%) is considered satisfactory.
Reducing Debt: A006620's debt to equity ratio has increased from 31.6% to 38% over the past 5 years.
Debt Coverage: A006620's debt is not well covered by operating cash flow (8.5%).
Interest Coverage: A006620's interest payments on its debt are well covered by EBIT (10.1x coverage).